Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Zhejiang DTRM Biopharma
miRagen Therapeutics, Inc.
miRagen Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Barbara Ann Karmanos Cancer Institute
Seagen Inc.
National Cancer Institute (NCI)
HemaQuest Pharmaceuticals Inc.